This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nektar (NKTR) Down 16.1% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar (NKTR) reports encouraging fourth-quarter results. The company continues to progress with its pipeline candidates.
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 7.25% and 28.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.
Alkermes (ALKS) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.
Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
Nektar's Pain Drug Gets Adverse Advisory Committee Decision
by Zacks Equity Research
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration
by Zacks Equity Research
Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.
Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On
by Sweta Killa
Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.
5 Losing Stocks From 2019 to Rebound Next Year
by Maharathi Basu
The positive sentiment witnessed by Wall Street in 2019 might be prevalent in 2020 as well owing to multiple tailwinds.
Why Is Nektar (NKTR) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News For Nov 12, 2019
by Zacks Equity Research
Companies In The News Are: QRTEA, FOLD, NKTR, WBA, KKR.
Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 23.29% and 11.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar's Shares Drop on Rating Downgrade by Goldman Sachs
by Zacks Equity Research
Nektar (NKTR) continues its downfall in 2019. Goldman Sachs downgrades the company's rating from Buy to Sell.
Company News For Sep 30, 2019
by Zacks Equity Research
Companies In The News Are: WFC,PFE,LTM,DAL,LVS,NKTR
Nektar Stock Down on Disappointing Breast Cancer Study Data
by Zacks Equity Research
Nektar Therapeutics (NKTR) presents preliminary data on triple negative breast cancer patients from an early-stage study, which fails to impress investors.
Why Is Nektar (NKTR) Down 42.5% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 21.25% and -10.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?